Prescribing Authority for Pharmacists as Viewed by Organized Pharmacy,Organized Medicine,and the Pharmaceutical Industry

Abstract

Spanish

French

This study identifies attitudes of organized pharmacy, organized medicine, and the pharmaceutical industry about prescribing authority for pharmacists. A questionnaire designed to assess the impact of a legislative bill permitting a pharmacist in an organized health care setting to initiate or modify drug therapy was mailed to state pharmacy associations, state hospital pharmacy associations, state pharmacy boards, state medical associations, Pharmaceutical Manufacturers Association (PMA)-member manufacturers, and non-PMA-member generic manufacturers. Responses from 194 of the 307 invited organizations were used. The six organization types viewed the impact of the legislative bill differently (p < 0.05). Hospital pharmacy associations and boards of pharmacy, to a lesser extent, supported the legislative bill; non-PMA-member generic manufacturers and state pharmacy associations were relatively neutral. The medical associations and the PMA-member companies opposed the passage of the bill. Furthermore, medical associations believed that the bill would not be passed in the majority of states in the next five years.

Get full access to this article

View all access options for this article.

References

Francke

. The pharmacist prescriber. Drug Intell Clin Pharm 1986; 20: 981–2.

White

. The pharmacist prescriber: a family pharmacist takes a critical look at the report of the Study Commission on Pharmacy. Drug Intell Clin Pharm 1986; 20: 982–3.

Doering

. Pharmacists as prescribers: the Florida experience. Drug Intell Clin Pharm 1986; 20: 983–4.

Stimmel

, Mcghan

. The pharmacist as prescriber of drug therapy: the USC pilot project. Drug Intell Clin Pharm 1981; 15: 665–72.

Zellmer

. Prescribing pharmacists. Am J Hosp Pharm 1982; 32: 1481.

Thompson

, Mcghan

, Ruffalo

, Cohen

, Adamcik

, Segal

. Clinical pharmacist prescribing drug therapy in a geriatric setting: outcome of a trial. J Am Geriatr Soc 1984; 32: 154–9.

Stimmel

, Mcghan

, Wincor

, Deandrea

. Comparison of pharmacist and physician prescribing for psychiatric inpatients. Am J Hosp Pharm 1982; 39: 1483–6.

Mcghan

, Stimmel

, Hall

, Gilman

. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care 1983; 21: 435–44.

Erickson

. Primary care by a pharmacist in an outpatient clinic. Am J Hosp Pharm 1977; 34: 1086–90.

10.

Conte

. Training and activities of pharmacist prescribers in a California pilot project. Am J Hosp Pharm 1986; 43: 375–80.

11.

Werble

AMA opposition to therapeutic substitution is “not negotiable.”

FDC Rep 1986; 48: 1–11.

12.

Levy

Therapeutic substitution: the price of cost containment.

Pharm Exec 1986; 6(4): 80–4.

13.

Therapeutic substitution symposium. Boston, MA: Medicine in the Public Interest, 1986.

14.

Grines

. Perceptions of therapeutic substitution and pharmacist prescribing: a comparison of pharmacy, medicine, and the pharmaceutical industry [M.S. thesis]. Columbus: Ohio State University, 1986.

15.

Therapeutic substitution destroys the authority of the physician's prescription.

Priv Pract 1985; 17(9): SP1-2.

16.

Covington

. Toward a rational approach to the issue of prescribing authority for pharmacists. Drug Intell Clin Pharm 1983; 17: 660–6.

17.

Stimmel

. Political and legal aspects of pharmacist prescribing. Am J Hosp Pharm 1983; 40: 1343–4.